The proposed mechanism centers on modulation of the nitric oxide system: BPC-157 counteracts L-NAME-induced eNOS blockade in rat models and supports vascular sprouting through VEGFR2 internalization (Hsieh et al., J Mol Med , 2017)
Since compounding pharmacies are regulated by state boards rather than the FDA, they can produce BPC-157 despite its unapproved status and associated quality control concerns
What makes it remarkable is its simplicity: glutathione is a tripeptide , built from just three amino acids cysteine, glutamic acid, and glycine
Degraded peptide may have lost its copper-binding capacity, creating a solution of free copper rather than beneficial GHK-CU complex
BPC-157 supports this interconnected system by: Strengthening tight junctions between intestinal epithelial cells, reducing intestinal permeability (leaky gut) Modulating the enteric nervous system to normalize motility and reduce visceral hypersensitivity Regulating mucosal immune responses to prevent inappropriate inflammation against dietary and microbial antigens Conditions Treated with Oral BPC-157 Beyond Symptom Relief: Addressing Root Causes Unlike proton pump inhibitors (PPIs) that suppress stomach acid or corticosteroids that broadly dampen immunity, BPC-157 works by restoring the underlying structural and functional integrity of the gastrointestinal tract
